Pembrolizumab-induced simultaneous and multiple immune-related adverse events including myasthenia gravis, myositis, hepatitis, and pityriasis lichenoides in a non-small cell lung cancer patient. - Han MR; Lee CH; Jeon SY; Yhim HY; Lee NR; Kwak JY; Park HS; Song EK (Archive of clinical cases, 2025)